Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.

Patients were randomly assigned to the nafamostat mesilate (NM) group or the no anticoagulant (NA) group. In patients assigned to the NM group, NM (20mg/h) was used for maintenance anticoagulation. Whereas, in patients assigned to the NA group, normal saline (2mL/h) was infused for continuous renal replacement therapy.

Inclusion Criteria:

• Patients who were admitted to the intensive care unit and required CRRT

  1. active bleeding such as gastrointestinal bleeding and intracranial hemorrhage,
  2. activated partial thromboplastin time > 60 s,
  3. prothrombin time-international normalized ratio > 2.0,
  4. thrombocytopenia (<100,000/µL), and
  5. surgery within 48 h before CRRT.

Exclusion Criteria:

• Pregnant or possibly pregnant women
• Patients who were allergic to nafamostat mesilate
• Patients who were hypercoagulable